Poseida Therapeutics, Inc. (NASDAQ:PSTX – Get Rating) Chairman Eric Ostertag sold 160,696 shares of Poseida Therapeutics stock in a transaction that occurred on Wednesday, August 3rd. The stock was sold at an average price of $3.69, for a total transaction of $592,968.24. Following the transaction, the chairman now owns 695,967 shares in the company, valued at $2,568,118.23. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.
Poseida Therapeutics Stock Performance
PSTX stock opened at $4.11 on Friday. The company has a quick ratio of 4.34, a current ratio of 4.34 and a debt-to-equity ratio of 0.56. Poseida Therapeutics, Inc. has a 1 year low of $1.82 and a 1 year high of $11.10. The company has a fifty day simple moving average of $2.56 and a 200 day simple moving average of $3.30.
Poseida Therapeutics (NASDAQ:PSTX – Get Rating) last released its quarterly earnings data on Thursday, May 12th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by ($0.35). The company had revenue of $1.44 million for the quarter, compared to analyst estimates of $2.50 million. As a group, research analysts expect that Poseida Therapeutics, Inc. will post -3.53 EPS for the current fiscal year.
Institutional Inflows and Outflows
Analyst Upgrades and Downgrades
Several equities analysts have weighed in on PSTX shares. BTIG Research lowered their price objective on shares of Poseida Therapeutics from $40.00 to $20.00 and set a “buy” rating on the stock in a research report on Friday, May 13th. Cantor Fitzgerald assumed coverage on shares of Poseida Therapeutics in a research note on Friday, May 13th. They set a “buy” rating and a $24.00 target price for the company. Finally, Piper Sandler decreased their target price on shares of Poseida Therapeutics from $19.00 to $9.00 in a research note on Friday, May 13th.
Poseida Therapeutics Company Profile
Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
- Get a free copy of the StockNews.com research report on Poseida Therapeutics (PSTX)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Poseida Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Poseida Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.